Navigation Links
Varian Medical Systems Publishes First Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements
Date:10/19/2011

PALO ALTO, Calif., Oct. 19 2011 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR), a world leader in radiotherapy and X-Ray imaging technology, is announcing the publication of its first comprehensive Corporate Social Responsibility (CSR) report, detailing the company's policies and achievements in extending care, protecting resources and helping to save lives. The 'Varian Sustainability' Report has been produced as part of the wider investment to continually improve sustainability performance and transparency.

"We have a responsibility to achieve our business goals in a socially and environmentally responsible manner," says Tim Guertin, chief executive officer of Varian Medical Systems. "While our company continues to develop better therapeutic capabilities for fighting cancer and other diseases as well as better components for X-Ray imaging, we strive to do so in ways which extend access to advanced care, improve clinical outcomes, optimize safety and make a positive impact on the communities where we operate."

In 2010, Varian commenced a company-wide undertaking to examine sustainability performance and identify challenges and opportunities to be addressed over time. This effort involved the close participation of senior leaders from all divisions, key geographies, and core functions.

The report, based on internationally-recognized GRI (global reporting initiative) parameters, reiterates the company's stated mission to help save an additional 100,000 lives each year, while outlining the governance structure that determines Varian's sustainability activities and setting goals for future achievements. The report's content is divided into four key areas: environmental, health access and outcomes, safety and responsibility, and colleagues and communities.

The report is available for customers, investors, and the general public at www.varian.com/sustainability. Varian plans to update its sustainability report in mid-2012.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.


'/>"/>
SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/30/2017)... 30, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... Healthcare Conference on Tuesday, June 13, 2017, in ... Hill-Rom,s president and chief executive officer, is scheduled to present ... webcast can be accessed at http://ir.hill-rom.com/events.cfm . A recorded ... live event through September 13, 2017. ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... June 20, 2017 , ... Dr. Manju R. ... for leading-edge care, whether or not they have a referral. Dr. Kejriwal offers ... iPlus™ laser, she targets bacteria and damaged tissue without affecting the surrounding tissue. ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that ... Denville, NJ, Drs. Adam and Hal Kimowitz are currently accepting new patients at their ... orthodontics can cause for some patients, which is why they offer the latest in ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants in ... on finding product improvements that could reduce the occurrence of unplanned extubations (UEs). ... help breathing or to provide medication. Sometimes, patient movement can cause unplanned extubations ...
(Date:6/20/2017)... ... 20, 2017 , ... In his newly appointed role as ... Ph.D., recently accepted the distinguished Sun Corridor Export Award for his company’s global ... and 16 other businesses from Pima, Pinal, and Maricopa counties in Arizona, and ...
(Date:6/20/2017)... ... June 20, 2017 , ... Total Security Integrated Systems, ... as the partner of choice by Amtrak to fulfill several projects in various ... and long-distance intercity service in the contiguous United States. Security Executives at the ...
Breaking Medicine News(10 mins):